HealthCare Journey for Multiple Sclerosis
  • Home
  • About Us
  • Virtual MS Center
    • Q & A for Virtual MS Center
    • Read About Our Virtual MS Center Staff
  • News & Resources
  • Health & Wellness
  • Blogs
    • Physician Blog >
      • Healthcare Provider Blog
    • Physical Therapy Blog
    • Patient Blog
    • Caregiver Blog
    • Research Blogs >
      • "Ask Dr. Debbie" Research Blog
      • Multiple Perspectives In Multiple Sclerosis Research Blog
  • About MS
    • What is MS?
    • Diagnosis
    • Treatment
    • MS Tips
  • Symptoms
    • Balance and Walking Issues
    • Breathing/Respiratory
    • Bowel Dysfunction
    • Cognitive Dysfunction
    • Crying/Laughing Uncontrollably (PBA)
    • Depression and Anxiety
    • Dizziness/Vertigo
    • Dysphagia
    • Fatigue
    • Foot Drop
    • Hearing or Smell or Taste Changes
    • Heat Sensitivity
    • Leg Weakness
    • Loss of Hand Dexterity and Coordination
    • Memory and Mutliple Sclerosis
    • Migraines
    • Numbness/Tingling/Altered Sensation
    • Nystagmus and Oscillopsia
    • Pain
    • Sexual Dysfunction
    • Sleep Issues
    • Spasticity/Spasms/Cramps
    • Speech/Swallowing
    • Urination/Bowel Problems
    • Vision
  • MS Clinics
  • MS Topics
    • Pregnancy and Infertility
    • Caregivers and Family Members
    • Employment and MS
    • Medical Costs and Insurance
    • Pediatric Multiple Sclerosis
  • Register With Us
  • Terms of Use/Privacy/HIPAA
  • MS HealthCare Journey

Welcome to the Virtual MS Center!

Ask any question you want about Multiple Sclerosis and one of our experts will answer it as soon as possible.
CLICK HERE TO ASK YOUR QUESTION!

What Are The Principal Findings Of The Study On Transitioning Patients From Tysabri To Tecfidera?

9/15/2014

 
Here is my question:
Hi, I just watched a short interview with Dr. Foley from Rocky Mountain MS center by Dr. Kantor at ECTRIMS. They were talking about Dr. Foley's study on transitioning patients from Tysabri to Tecfidera, but they didn't mention the principal findings. Do you know what they observed, or where we can find these results? Thank you!

Answer:
Dr Foley’s study showed that approximately 75 % of patients on long term Tysabri treatment were able to switch to Tecfidera and 25 % had to restart Tysabri because of recurrent disease activity.
38% of patients experienced a relapse after stopping Tysabri and switching to Tecfidera.
These numbers are similar to the rate of relapse observed when Tysabri treated patients are switched to other disease modifying therapies.

Below is the abstract and poster that was presented at ECTRIMS.

A PILOT STUDY TO ASSESS DISEASE STATE STABILITY, EFFICACY, AND TOLERABILITY IN A NATALIZUMAB TO DIMETHYL FUMARATE CROSSOVER DESIGN

JF Foley1, T Hoyt1, A Christensen2, D Blatter2
1Rocky Mountain MS Research Group, Salt Lake City, UT, United States, 2Mountain Medical Physician Specialists, Salt Lake City, UT, United States

Background: While natalizumab therapy is highly efficacious for the treatment of multiple sclerosis (MS), it does carry significant risk for progressive multifocal leukoencephalopathy (PML) in patients who have an immunosuppressant history, >=24 natalizumab doses, and JCV index of >=1.5. A crossover to dimethyl fumarate (DMF) is an option for many of these patients. The data regarding a crossover of this nature does not yet exist.

Objectives: To determine disease stability for 24 weeks in patients who have crossed over from natalizumab to dimethyl fumarate therapy.

Methods: 30 subjects at high risk (>2 years on therapy, JCV index >= 1.5) for developing PML on natalizumab were enrolled in a study to monitor their transition to dimethyl fumarate. Patients were observed for 24 weeks, starting from their last dose of natalizumab therapy. Outcome measures included disease stability defined by EDSS, annualized relapse  rate, modified fatigue impact scale (MFIS) and the symbol digit modalities test (SDMT), visual analog scale (VAS), and timed 25 foot walk test. MRI activity including spectroscopy was measured at Week 0, Week 4, Week 16, and Week 24.

Results: Of the 15 patients who have completed the study, mean MS disease duration was 16 years, mean number of natalizumab infusions was 67, and the mean length of the last 6 infusion cycles was 37 days. From the date of the last infusion, it took an average of 22 days to begin the 120 mg dose of DMF and another 6.8 days to titrate to the 240 mg dose. At baseline, the JCV index scores ranged from 1.24-3.95. EDSS score increased by 0.5 in 4 of the 15 subjects. Thus far, 2 of the 15 subjects have transitioned back to natalizumab.

Conclusions: The data lock completing the study will occur in August of 2014. All outcome measures will be presented.

You can download the poster (PDF below)
or go to the ECTRIMS website (see link below). The Poster Number is P877.

drfoley.pdf.pdf
File Size: 13582 kb
File Type: pdf
Download File

http://www.abstractstosubmit.com/msboston2014/eposter/

Comments are closed.

    RSS Feed

    PLEASE NOTE: This information/opinions on this site should be used as an information source only.  This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment.  Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.
    Read About Our Virtual MS Center Authors

    Archives

    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    July 2013
    June 2013

    Categories

    All
    Accessible Housing And Environmental Modifications
    Anxiety
    Balance
    Bowel Problems
    Caregivers
    Cognitive Function
    Compliance
    David Rintell Ed. D.
    Deborah Backus Blogs
    Depression
    Diagnosis
    Diet
    Dizziness
    Dosing
    Dr. Greenberg's Q&A
    Dr. Kinkel's Q&A
    Dr. Miravalle's Q&A
    Dr. Nielsen's Q&A
    Dr. Osborne's Q&A
    Exercise
    Experimental Treatments
    Eye Surgery
    Fatigue
    Fatique
    Flu Shot
    Foot Drop
    Herbs
    Immunosuppression
    JCV
    Lasik Surgery
    Lesions
    Lori Kostich's Q&A
    Lyme Disease
    Medications
    Migraines
    Mobility
    MRI
    MS Hug
    Other Diseases
    Pain
    PML
    PPMS
    Pregnancy
    Relapse
    Safety
    Sarah Wargo's Q&A
    Sexual Dysfunction
    Side Effects
    Smoking
    Spasticity
    Stem Cell Transplantation
    Steroids
    Stress
    Supplements
    Surgery
    Symptoms
    Treatment
    Urination
    Viruses
    Vision
    Vitamin D
    Vitamins
    Weakness


© 2020 HealthCare Journey, LLC. All Rights Reserved.
HealthCare Journey™ is a trademark of HealthCare Journey, LLC
Picture
  • Home
  • About Us
  • Virtual MS Center
    • Q & A for Virtual MS Center
    • Read About Our Virtual MS Center Staff
  • News & Resources
  • Health & Wellness
  • Blogs
    • Physician Blog >
      • Healthcare Provider Blog
    • Physical Therapy Blog
    • Patient Blog
    • Caregiver Blog
    • Research Blogs >
      • "Ask Dr. Debbie" Research Blog
      • Multiple Perspectives In Multiple Sclerosis Research Blog
  • About MS
    • What is MS?
    • Diagnosis
    • Treatment
    • MS Tips
  • Symptoms
    • Balance and Walking Issues
    • Breathing/Respiratory
    • Bowel Dysfunction
    • Cognitive Dysfunction
    • Crying/Laughing Uncontrollably (PBA)
    • Depression and Anxiety
    • Dizziness/Vertigo
    • Dysphagia
    • Fatigue
    • Foot Drop
    • Hearing or Smell or Taste Changes
    • Heat Sensitivity
    • Leg Weakness
    • Loss of Hand Dexterity and Coordination
    • Memory and Mutliple Sclerosis
    • Migraines
    • Numbness/Tingling/Altered Sensation
    • Nystagmus and Oscillopsia
    • Pain
    • Sexual Dysfunction
    • Sleep Issues
    • Spasticity/Spasms/Cramps
    • Speech/Swallowing
    • Urination/Bowel Problems
    • Vision
  • MS Clinics
  • MS Topics
    • Pregnancy and Infertility
    • Caregivers and Family Members
    • Employment and MS
    • Medical Costs and Insurance
    • Pediatric Multiple Sclerosis
  • Register With Us
  • Terms of Use/Privacy/HIPAA
  • MS HealthCare Journey